BL-B16D1

N/A

Report date: 2025/03/03 11:05:43

Base Information

Drug NameBL-B16D1
Drug Alias NameBL-B16D1BLB16D1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsReceptor tyrosine-protein kinase erbB-3 modulators
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBaili-Bio (Chengdu) Pharmaceutical Co LtdSichuan Baili Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBaili-Bio (Chengdu) Pharmaceutical Co LtdSichuan Baili Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursBreast NeoplasmsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A